Clinical Trial

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Natalie YL Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana GZ Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael Friedlander, Kidong Kim, David SP Tan

10.1136/ijgc-2020-001604

June 25, 2020

Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol

Anette Stolberg Kargo, Angela Coulter, Kristina Lindemann, Pernille Tine Jensen, Niels Henrik Hjøllund, Berit Jul Mosgaard, Karina Dahl Steffensen

10.1136/ijgc-2020-001528

June 24, 2020

A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, Antonio Casado, Annekke Westermann, Nicolas Isambert, Paolo Giovanni Casali, Sarah Pratap, Daniel Stark, Claudia Valverde, Anjana Anand, Manon Huizing, Anne Floquet, Lars Lindner, Barbara Hermes, Beatrice Seddon, Corneel Coens, Robin Jones, Nick Reed

10.1136/ijgc-2020-001519

June 15, 2020

Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study

Hua Tu, He Huang, Yi Ouyang, Qing Liu, Bingna Xian, Kun Song, Gang Chen, Yuanming Shen, Jihong Liu

10.1136/ijgc-2020-001357

June 9, 2020

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study

Jyoti Mayadev, Ana T Nunes, Mary Li, Michelle Marcovitz, Mark C Lanasa, Bradley J Monk

10.1136/ijgc-2019-001135

May 23, 2020

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Simone Koole, Ruby van Stein, Karolina Sikorska, Desmond Barton, Lewis Perrin, Donal Brennan, Oliver Zivanovic, Berit Jul Mosgaard, Anna Fagotti, Pierre-Emmanuel Colombo, Gabe Sonke, W J van Driel, on behalf of the OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, N Bakrin, S Banerjee, S Barry, DP Barton, D Brennan, PE Colombo, M Deraco, WJ van Driel, A Fagotti, R Farrell, R Grisham, BJ Mosgaard, I McNeish, L Perrin, GS Sonke, O Zivanovic, HJG Arts, I Boere, GJ Creemers, WJ van Driel, KN Gaarenstroom, M van Gent, M van Ham, B Hellebrekers, R Hermans, I de Hingh, SN Koole, JR Kroep, CD de Kroon, R Lalisang, S Lambrechts, P Ottevanger, N Reesink, V Retel, AKL Reyners, EM Roes, HWR Schreuder, GS Sonke, RM van Stein, A Thijs, A Westermann, PO Witteveen, A Wymenga, R Yigit

10.1136/ijgc-2020-001231

March 23, 2020